vs
Pursuit Attractions & Hospitality, Inc.（PRSU）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Pursuit Attractions & Hospitality, Inc.的季度营收约是REGENXBIO Inc.的1.9倍（$57.1M vs $30.3M），Pursuit Attractions & Hospitality, Inc.净利率更高（-45.9% vs -221.3%，领先175.5%），REGENXBIO Inc.同比增速更快（43.0% vs 24.6%），Pursuit Attractions & Hospitality, Inc.自由现金流更多（$-44.6M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -53.2%）
珀西尤特景点 hospitality 公司是一家全球性景点与酒店管理企业，业务布局加拿大、美国、冰岛与哥斯达黎加。公司在加拿大落基山脉的班夫、贾斯珀、沃特顿，阿拉斯加的迪纳利、基奈峡湾国家公园沿线，蒙大拿冰川景区，冰岛以及哥斯达黎加阿雷纳尔地区，自营景点、住宿、餐饮、零售与交通业务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
PRSU vs RGNX — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $57.1M | $30.3M |
| 净利润 | $-26.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -49.5% | -190.0% |
| 净利率 | -45.9% | -221.3% |
| 营收同比 | 24.6% | 43.0% |
| 净利润同比 | -108.4% | -31.2% |
| 每股收益（稀释后） | $-0.89 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $57.1M | $30.3M | ||
| Q3 25 | $241.0M | $29.7M | ||
| Q2 25 | $116.7M | $21.4M | ||
| Q1 25 | — | $89.0M | ||
| Q4 24 | — | $21.2M | ||
| Q3 24 | $182.3M | $24.2M | ||
| Q2 24 | $101.2M | $22.3M | ||
| Q1 24 | — | $15.6M |
| Q4 25 | $-26.2M | $-67.1M | ||
| Q3 25 | $73.9M | $-61.9M | ||
| Q2 25 | $5.6M | $-70.9M | ||
| Q1 25 | — | $6.1M | ||
| Q4 24 | — | $-51.2M | ||
| Q3 24 | $48.6M | $-59.6M | ||
| Q2 24 | $29.3M | $-53.0M | ||
| Q1 24 | — | $-63.3M |
| Q4 25 | — | — | ||
| Q3 25 | 91.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | 90.7% | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
| Q4 25 | -49.5% | -190.0% | ||
| Q3 25 | 43.9% | -176.3% | ||
| Q2 25 | 9.1% | -296.3% | ||
| Q1 25 | — | 13.6% | ||
| Q4 24 | — | -242.1% | ||
| Q3 24 | 50.8% | -256.6% | ||
| Q2 24 | 52.8% | -251.3% | ||
| Q1 24 | — | -408.8% |
| Q4 25 | -45.9% | -221.3% | ||
| Q3 25 | 30.6% | -208.3% | ||
| Q2 25 | 4.8% | -331.8% | ||
| Q1 25 | — | 6.8% | ||
| Q4 24 | — | -241.3% | ||
| Q3 24 | 26.7% | -246.3% | ||
| Q2 24 | 29.0% | -237.7% | ||
| Q1 24 | — | -405.4% |
| Q4 25 | $-0.89 | $-1.30 | ||
| Q3 25 | $2.60 | $-1.20 | ||
| Q2 25 | $0.20 | $-1.38 | ||
| Q1 25 | — | $0.12 | ||
| Q4 24 | — | $-0.99 | ||
| Q3 24 | $1.65 | $-1.17 | ||
| Q2 24 | $0.98 | $-1.05 | ||
| Q1 24 | — | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.1M | $230.1M |
| 总债务越低越好 | $155.0M | — |
| 股东权益账面价值 | $581.8M | $102.7M |
| 总资产 | $965.4M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.27× | — |
8季度趋势，按日历期对齐
| Q4 25 | $31.1M | $230.1M | ||
| Q3 25 | $33.8M | $274.2M | ||
| Q2 25 | $24.7M | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | — | $234.7M | ||
| Q3 24 | $64.6M | $255.5M | ||
| Q2 24 | $59.4M | $290.4M | ||
| Q1 24 | — | $338.7M |
| Q4 25 | $155.0M | — | ||
| Q3 25 | $124.5M | — | ||
| Q2 25 | $82.4M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $381.9M | — | ||
| Q2 24 | $469.3M | — | ||
| Q1 24 | — | — |
| Q4 25 | $581.8M | $102.7M | ||
| Q3 25 | $607.2M | $161.5M | ||
| Q2 25 | $528.4M | $213.7M | ||
| Q1 25 | — | $274.2M | ||
| Q4 24 | — | $259.7M | ||
| Q3 24 | $96.8M | $301.4M | ||
| Q2 24 | $41.2M | $348.3M | ||
| Q1 24 | — | $390.7M |
| Q4 25 | $965.4M | $453.0M | ||
| Q3 25 | $996.8M | $525.2M | ||
| Q2 25 | $893.1M | $581.0M | ||
| Q1 25 | — | $490.9M | ||
| Q4 24 | — | $466.0M | ||
| Q3 24 | $1.2B | $519.1M | ||
| Q2 24 | $1.2B | $569.4M | ||
| Q1 24 | — | $629.2M |
| Q4 25 | 0.27× | — | ||
| Q3 25 | 0.21× | — | ||
| Q2 25 | 0.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.95× | — | ||
| Q2 24 | 11.39× | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-13.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-44.6M | $-52.8M |
| 自由现金流率自由现金流/营收 | -78.1% | -174.0% |
| 资本支出强度资本支出/营收 | 54.2% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $140.9M | $-126.4M |
8季度趋势，按日历期对齐
| Q4 25 | $-13.6M | $-52.3M | ||
| Q3 25 | $102.6M | $-56.0M | ||
| Q2 25 | $21.6M | $-49.3M | ||
| Q1 25 | — | $33.6M | ||
| Q4 24 | — | $-31.6M | ||
| Q3 24 | $110.4M | $-40.5M | ||
| Q2 24 | $30.3M | $-45.5M | ||
| Q1 24 | — | $-55.5M |
| Q4 25 | $-44.6M | $-52.8M | ||
| Q3 25 | $86.8M | $-56.5M | ||
| Q2 25 | $3.2M | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | $95.4M | $-40.9M | ||
| Q2 24 | $13.1M | $-46.0M | ||
| Q1 24 | — | $-56.0M |
| Q4 25 | -78.1% | -174.0% | ||
| Q3 25 | 36.0% | -189.9% | ||
| Q2 25 | 2.8% | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | 52.4% | -168.9% | ||
| Q2 24 | 13.0% | -206.2% | ||
| Q1 24 | — | -358.5% |
| Q4 25 | 54.2% | 1.7% | ||
| Q3 25 | 6.6% | 1.7% | ||
| Q2 25 | 15.7% | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | 8.2% | 1.3% | ||
| Q2 24 | 16.9% | 2.1% | ||
| Q1 24 | — | 3.6% |
| Q4 25 | — | — | ||
| Q3 25 | 1.39× | — | ||
| Q2 25 | 3.83× | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.27× | — | ||
| Q2 24 | 1.03× | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRSU
| Services Transferred Over Time | $44.7M | 78% |
| Food And Beverage | $9.1M | 16% |
| Retail Operations | $3.3M | 6% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
